Form 4 Filing for Lexeo Therapeutics, Inc.

This Form 4 filing details a stock option grant to Louis Edward Tamayo, the Chief Financial Officer of Lexeo Therapeutics, Inc. The option, granted on September 24, 2026, is for 54,750 shares of Common Stock with an exercise price of $3.39. The option has an expiration date of September 23, 2036. Vesting commences on September 24, 2027, with 25% vesting immediately and the remainder vesting in monthly installments over the subsequent year, contingent upon continued service. Following the transaction, Mr. Tamayo holds 54,750 shares underlying this option.